Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC CHARACTERISTICS, AND PRELIMINARY ANTI-TUMOR EFFICACY OF HEMAY5087 IN PATIENTS WITH ADVANCED SOLID TUMORS

NCT07624864 is registered in ClinicalTrials.gov with Ganzhou Hemay Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07624864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07624864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC CHARACTERISTICS, AND PRELIMINARY ANTI-TUMOR EFFICACY OF HEMAY5087 IN PATIENTS WITH ADVANCED SOLID TUMORS
Lead sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 15, 2026
Completion date
June 30, 2028
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors